Literature DB >> 25483530

Potential effect of PCV13 introduction on Emergency Department accesses for lower respiratory tract infections in elderly and at risk adults.

Filippo Ansaldi1, Andrea Orsi, Cecilia Trucchi, Daniela De Florentiis, Antonella Ceravolo, Martina Coppelli, Sergio Schiaffino, Valter Turello, Roberto Rosselli, Roberto Carloni, Giancarlo Icardi, Ligurian Pneumococcal Study Group, Paola Canepa, Laura Sticchi, Roberta Zanetti, Ilaria Cremonesi, PierClaudio Brasesco, Paolo Moscatelli.   

Abstract

Liguria, an administrative region in northern Italy characterized by a decade of high PCV coverage in paediatric age group, has issued new PCV13 recommendations for free active immunization in adults with risk factors and subjects aged ≥ 70 years old. Main aims of this study are: (1) a descriptive epidemiology of the clinical burden of lower respiratory tract infections (LRTI) in adults ≥18 years of age; and (2) a crossover evaluation of the effect of introduction of PCV13 vaccination in adults aged ≥70 years old, in terms of ED accesses for LRTI, obtained by a Syndrome Surveillance System (SSS). The ED access, chief complaint based SSS will allow an active surveillance of a population cohort of >430 000 individuals resident in Genoa metropolitan area, aged ≥18 years old, for a period of 60 months. During pre-PCV period, annual cumulative incidence of ED accesses for LRTI was equal to 7/1000 and 2% in ≥65 and ≥85 year adults, respectively. In ≥65 years adults, more than 70% of subjects identified by the SSS has at least one risk condition, with a peak of 87% in ≥85 year cohort. New Ligurian PCV13 recommendations can potentially reach more than 75% of ED accesses for LRTI. Data highlights the heavy impact of LRTI in terms of ED accesses, especially in the elderly and subjects with chronic conditions and the usefulness of SSS tool for monitoring PCV vaccination effect.

Entities:  

Keywords:  hospital access; lower respiratory tract infections; pneumococcal vaccination; pneumonia; syndrome surveillance

Mesh:

Substances:

Year:  2014        PMID: 25483530      PMCID: PMC4514222          DOI: 10.4161/hv.34419

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  36 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 2.  Community-acquired pneumonia in Europe: causative pathogens and resistance patterns.

Authors:  M Woodhead
Journal:  Eur Respir J Suppl       Date:  2002-07

3.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

Authors:  B J Marston; J F Plouffe; T M File; B A Hackman; S J Salstrom; H B Lipman; M S Kolczak; R F Breiman
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

4.  Statin treatment and reduced risk of pneumonia in patients with diabetes.

Authors:  E M W van de Garde; E Hak; P C Souverein; A W Hoes; J M M van den Bosch; H G M Leufkens
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

Review 5.  Community-acquired pneumonia.

Authors:  J G Bartlett; L M Mundy
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines.

Authors:  W S Lim; J T Macfarlane; T C Boswell; T G Harrison; D Rose; M Leinonen; P Saikku
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

7.  Hospital admissions for pneumonia in Spain.

Authors:  V Monge; A González
Journal:  Infection       Date:  2001 Jan-Feb       Impact factor: 3.553

8.  Risk factors for community-acquired pneumonia in German adults: the impact of children in the household.

Authors:  M Schnoor; T Klante; M Beckmann; B P Robra; T Welte; H Raspe; T Schäfer
Journal:  Epidemiol Infect       Date:  2007-02-12       Impact factor: 2.451

9.  Statins and the risk of pneumonia: a population-based, nested case-control study.

Authors:  Raymond G Schlienger; David S Fedson; Susan S Jick; Hershel Jick; Christoph R Meier
Journal:  Pharmacotherapy       Date:  2007-03       Impact factor: 4.705

10.  Type 2 diabetes and pneumonia outcomes: a population-based cohort study.

Authors:  Jette B Kornum; Reimar W Thomsen; Anders Riis; Hans-Henrik Lervang; Henrik C Schønheyder; Henrik T Sørensen
Journal:  Diabetes Care       Date:  2007-06-26       Impact factor: 19.112

View more
  6 in total

Review 1.  Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Authors:  Susanna Esposito; Paolo Bonanni; Stefania Maggi; Litjan Tan; Filippo Ansaldi; Pier Luigi Lopalco; Ron Dagan; Jean-Pierre Michel; Pierre van Damme; Jacques Gaillat; Roman Prymula; Timo Vesikari; Cristina Mussini; Uwe Frank; Albert Osterhaus; Lucia Pastore Celentano; Marta Rossi; Valentina Guercio; Gaetan Gavazzi
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

Review 2.  Methodological criticisms in the evaluation of Pneumococcal Conjugate Vaccine effectiveness.

Authors:  C Trucchi; C Paganino; F Ansaldi
Journal:  J Prev Med Hyg       Date:  2015-08-31

3.  Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy.

Authors:  Cecilia Trucchi; Cristiano Alicino; Andrea Orsi; Chiara Paganino; Ilaria Barberis; Federico Grammatico; Paola Canepa; Emanuela Rappazzo; Bianca Bruzzone; Laura Sticchi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

4.  Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old.

Authors:  Cecilia Trucchi; Chiara Paganino; Andrea Orsi; Daniela Amicizia; Valentino Tisa; Maria Francesca Piazza; Domenico Gallo; Simona Simonetti; Bruno Buonopane; Giancarlo Icardi; Filippo Ansaldi
Journal:  BMC Health Serv Res       Date:  2019-08-19       Impact factor: 2.655

Review 5.  Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination.

Authors:  Andrea Orsi; Filippo Ansaldi; Cecilia Trucchi; Roberto Rosselli; Giancarlo Icardi
Journal:  Int J Mol Sci       Date:  2016-07-15       Impact factor: 5.923

6.  Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region.

Authors:  Cecilia Trucchi; Marco D'Amelio; Daniela Amicizia; Andrea Orsi; Idalba Loiacono; Roberta Tosatto; Maria Francesca Piazza; Chiara Paganino; Andrea Pitrelli; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.